53542
document
Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion -- CAtholic Total Occlusion Study ( CATOS ) trial . BACKGROUND Limited data are available regarding the direct comparison of angiographic and clinical outcomes after percutaneous coronary intervention ( PCI ) with drug-eluting stents ( DESs ) for chronic total occlusion ( CTO ) . METHODS AND RESULTS A prospective , randomized , multicenter trial was conducted to evaluate the non-inferiority of a zotarolimus-eluting stent ( ZES ; Endeavor Sprint® , n=80 ) to a sirolimus-eluting stent ( SES ; Cypher® , n=80 ) in patients with CTO lesion with a reference vessel diameter ≥ 2.5mm . The primary endpoint was in-segment binary restenosis rate at 9-month angiographic follow-up . Key secondary endpoints included target vessel failure ( TVF ; including cardiac death , myocardial infarction , and target vessel revascularization ) and Academic Research Consortium-defined definite/probable stent thrombosis ( ST ) within 12 months . The ZES was non-inferior to the SES with respect to the primary endpoint , which occurred in 14.1 % ( 95 % confidence interval [ CI ] : 6.0-22.2 ) and in 13.7 % ( 95 % CI : 5.8-21.6 ) of patients , respectively ( non-inferiority margin , 15.0 % ; P for non-inferiority < 0.001 ) . There were no significant between-group differences in the rate of TVF ( 10.0 % vs. 17.5 % ; P=0.168 ) nor in the rate of ST ( 0.0 % vs. 1.3 % ; P=0.316 ) during the 12-month clinical follow-up . CONCLUSIONS The effectiveness and safety of ZES are similar to those of SES and therefore it is a good treatment option in patients undergoing PCI for CTO with DESs .
53543
Intervention_Pharmacological
zotarolimus-eluting stents
53544
Intervention_Pharmacological
sirolimus-eluting stents
53545
Intervention_Pharmacological
drug-eluting stents
53546
Intervention_Physical
zotarolimus-eluting stent
53547
Intervention_Physical
sirolimus-eluting stent
53548
Outcome_Other
efficacy and safety
53549
Outcome_Physical
in-segment binary restenosis rate
53550
Outcome_Physical
target vessel failure ( TVF ; including cardiac death , myocardial infarction , and target vessel revascularization )
53551
Outcome_Physical
Academic Research Consortium-defined definite/probable stent thrombosis ( ST )